

Upcoming changes to medical pharmacy prior authorization, claims editing

Security Health Plan requires prior authorization (PA) and post-service claim edits (PSCE) for certain office-administered, medically billed medications to ensure appropriate coverage and payment. The following changes, effective **Oct. 15, 2026**, unless otherwise noted, will occur within the medical pharmacy program administered by Prime Therapeutics.

The following drugs will be a benefit exclusion:

- Avlayah
- Loargys

The following drugs will require a prior authorization and post-service claim edit:

- Flebogamma
- Triluron
- Qivigy
- Qutenza

Prime Therapeutics, Security Health Plan's specialty pharmacy partner, manages prior authorization for the medical pharmacy medications listed above. For questions, call **(800) 424-8243** or visit the Prime Therapeutics website.

Medical-to-pharmacy benefit transition: the following medications will no longer be reviewed by Prime Therapeutics under the medical benefit and will require authorization through the pharmacy benefit:

- Acthar HP
- Adbry
- Cortrophin Gel
- Enspryng
- Firazyr
- Haegarda
- Takhzyro
- Winrevair

Effective Nov. 1, 2026 Prime Therapeutics will no longer review Xgeva or its biosimilars under the medical pharmacy program.

- **Preferred biosimilars** (Osenvelt and Wyost) will not require prior authorization.
- **Non-preferred products** (Xgeva, Aukelso, Bilprevda, Bomynta, Jubereq, Oziltus, Xbryk and Xtrenbo) should be submitted to **Eviti** for review.

A complete list of medications requiring a prior authorization or post-service claim edits is available on [Security Health Plan's website](#). For questions regarding pharmacy benefit medications, please contact the Security Health Plan pharmacy team at **(877) 873-5611**.